Ian Sherwin

Partner

New York

A member of the firm’s Global Corporate Group, Ian’s practice focuses on executive compensation and employee benefits matters in connection with mergers and acquisitions and other transactions, primarily with respect to private equity sponsors and their portfolio companies. He also advises clients on the design, implementation, and disclosure and taxation of equity and cash-based incentive compensation, deferred compensation programs, retention and transaction-based bonus programs, and the negotiation of executive employment, change in control, and separation agreements. Ian has expertise in the taxation rules governing executive compensation, including Code Sections 83, 280G, and 409A.

Experience

Representative matters

Represented Thoma Bravo in the sale of its portfolio company Ellie Mae to Intercontinental Exchange.
Represented Bristol-Myers Squibb in its $13.4 billion divestiture of Celgene’s OTEZLA® program to Amgen, in relation to its $90 billion acquisition of Celgene.
Represented Cambrex Corporation in its $2.4 billion agreement to be acquired by Permira.

Recognitions

  • Ranked in Chambers USA for New York Employee Benefits & Executive Compensation, 2025
  • Ranked in Chambers USA as Up and Coming for New York Employee Benefits & Executive Compensation, 2024
  • Selected for inclusion in the New York Metro Super Lawyers Rising Stars list for Employee Benefits, 2024

Credentials

Education

  • Georgetown University Law Center, 2012, LL.M., in Taxation with Certificate in Employee Benefits Law
  • Hofstra University School of Law, 2011, J.D.
  • University at Buffalo, The State University of New York, 2008, B.S.

Professional admissions & qualifications

  • New York
  • New Jersey

News